News/ News/ News/ Oncology/ R&D EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track Phil Taylor acute myeloid leukaemia, Astellas, Daiichi Sankyo, EHA 2022, FLT3 inhibitor, Novartis, quizartinib, Rydapt, Xospata 0 Comment Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the Share X EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track https://pharmaphorum.com/news/eha-survival-data-sets-daiichi-sankyos-quizartinib-back-on-track/